PBAC STAKEHOLDER MEETING OUTCOME STATEMENT RUXOLITINIB FOR MYELOFIBROSIS 22 September 2014 The Sheraton Hotel, Melbourne Attendees Members of the Pharmaceutical Benefits Advisory Committee (PBAC), the consumer

First Page		Document Content
Date: 2015-03-12 23:53:04 Pharmaceutical Benefits Scheme Pharmacology Myelofibrosis International Prognostic Scoring System IPSS Clinical trial Medicine Health Ruxolitinib		PBAC STAKEHOLDER MEETING OUTCOME STATEMENT RUXOLITINIB FOR MYELOFIBROSIS 22 September 2014 The Sheraton Hotel, Melbourne Attendees Members of the Pharmaceutical Benefits Advisory Committee (PBAC), the consumer Add to Reading List Source URL: pbs.gov.au Download Document from Source Website File Size: 349,88 KB Share Document on Facebook

	PDF Document DocID: 1xvUb - View Document
	PDF Document DocID: 1xc8R - View Document
	Institute of Pharmacology www.pki.unibe.ch Introduction Prof. Dr. Dr. Stephan von Gunten MD PhD MME DocID: 1vqsj - View Document
	Jansone et al.: Intrinsic Activity, 2017; 5 (Suppl.2):A1.6 doi:IA.5.S2-A1.6 published online: 16 October 2017 2nd International Conference in Pharmacology: From Cellular Processes to Drug Targets Rīga, Latvia DocID: 1vlJU - View Document
	Human cells Notable for research in: -Medecine: Diseases and cancers -Cell Biology -Pharmacology DocID: 1vk1K - View Document